METASTATIC ESOPHAGEAL ADENOCARCINOMA
Clinical trials for METASTATIC ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib combined with radiation for people with advanced esophageal or stomach cancer that cannot be removed by surgery. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, so result…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
New drug combo shows promise for tough esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with esophageal cancer that has spread. About 94 adults with metastatic esophageal or gastroesophageal junction cancer will receive either paclitaxel alone or paclitaxel plu…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New drug combo aims to shrink Hard-to-Treat esophageal tumors
Disease control OngoingThis study tests a combination of two drugs, abemaciclib and ramucirumab, in people with advanced esophageal or gastroesophageal junction cancer that has spread. The goal is to see if the combination is safe and can help control tumor growth. About 8 participants will receive the…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Radiation boost may extend life for limited-spread stomach and esophageal cancers
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2 negative esophageal or stomach cancer that has spread to only a few spots in the body. About 314 participants will receive either chemotherapy alone or chemotherapy plus radiation. T…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC